A detailed history of State Of Wisconsin Investment Board transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, State Of Wisconsin Investment Board holds 72,368 shares of RNA stock, worth $3.05 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
72,368
Previous 37,881 91.04%
Holding current value
$3.05 Million
Previous $1.55 Million 114.8%
% of portfolio
0.01%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$37.21 - $48.14 $1.28 Million - $1.66 Million
34,487 Added 91.04%
72,368 $3.32 Million
Q2 2024

Aug 14, 2024

BUY
$22.73 - $40.85 $72,054 - $129,494
3,170 Added 9.13%
37,881 $1.55 Million
Q1 2024

May 14, 2024

SELL
$9.16 - $25.52 $738,744 - $2.06 Million
-80,649 Reduced 69.91%
34,711 $885,000
Q4 2023

Feb 12, 2024

BUY
$4.87 - $9.37 $286,511 - $551,255
58,832 Added 104.08%
115,360 $1.04 Million
Q3 2023

Nov 14, 2023

BUY
$6.3 - $11.35 $50,362 - $90,731
7,994 Added 16.47%
56,528 $360,000
Q2 2023

Aug 14, 2023

SELL
$10.62 - $17.34 $85,416 - $139,465
-8,043 Reduced 14.22%
48,534 $538,000
Q1 2023

May 15, 2023

BUY
$15.35 - $25.65 $278,571 - $465,496
18,148 Added 47.22%
56,577 $868,000
Q4 2022

Feb 14, 2023

BUY
$10.06 - $22.66 $22,745 - $51,234
2,261 Added 6.25%
38,429 $852,000
Q3 2022

Nov 14, 2022

SELL
$15.46 - $23.43 $23,437 - $35,519
-1,516 Reduced 4.02%
36,168 $591,000
Q2 2022

Aug 15, 2022

SELL
$11.18 - $20.5 $16,948 - $31,078
-1,516 Reduced 3.87%
37,684 $548,000
Q2 2021

Aug 12, 2021

BUY
$19.62 - $29.26 $306,072 - $456,456
15,600 Added 66.1%
39,200 $969,000
Q4 2020

Feb 03, 2021

BUY
$24.73 - $35.12 $583,628 - $828,831
23,600 New
23,600 $602,000

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $2.2B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track State Of Wisconsin Investment Board Portfolio

Follow State Of Wisconsin Investment Board and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Wisconsin Investment Board, based on Form 13F filings with the SEC.

News

Stay updated on State Of Wisconsin Investment Board with notifications on news.